Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 18, 2018 at 10:03 AM.

  1. #1 cafead, Jul 18, 2018 at 10:03 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Five years after Eli Lilly stepped up with a $1.8 billion deal to bring Pfizer’s anti-NGF pain drug tanezumab back from limbo, the pharma giants are reporting that they successfully navigated a major Phase III study for the non-opioid therapy among patients suffering from osteoarthritis.

    article source
     
    Quote

Reply to Thread